Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Renal Cell 71 Prostatic Neoplasms 22 Kidney Neoplasms 14 Carcinoma, Transitional Cell 9 Urinary Bladder Neoplasms 7 Carcinoma, Non-Small-Cell Lung 7 Neoplasm Metastasis 6 Clear-cell metastatic renal cell carcinoma 6 Carcinoma, Hepatocellular 6 Urethral Neoplasms 4 Ovarian Neoplasms 4 Neoplasms 4 Colorectal Neoplasms 4 Triple Negative Breast Neoplasms 3 Breast Neoplasms 3 Brain Neoplasms 3 Wilms Tumor 2 Urologic Neoplasms 2 Urogenital Neoplasms 2 Ureteral Neoplasms 2 Small Cell Lung Carcinoma 2 Sarcoma, Ewing 2 Sarcoma 2 Rhabdomyosarcoma 2 Recurrence 2 Penile Neoplasms 2 Pancreatic Neoplasms 2 Pain 2 Osteosarcoma 2 Melanoma 2

Interventions

Gemcitabine 4 Cisplatin 4 pembrolizumab 3 Carboplatin 3 erdafitinib 2 durvalumab 2 vinflunine 1 tremelimumab 1 niraparib 1 enfortumab vedotin 1 cabozantinib 1 avelumab 1 atezolizumab 1 Tiragolumab 1 Sunitinib 1 Radiotherapy 1 Radiation Dose Hypofractionation 1 Paclitaxel 1 Nivolumab 1 Midazolam 1 Metformin 1 Ipilimumab 1 Everolimus 1 Docetaxel 1 4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Urothelial Cancer × cabozantinib × Genitourinary × Clear all

NCT03425201 2024-12-31

NICARAGUA

Fundacion CRIS de Investigación para Vencer el Cáncer

Phase 1/2 Completed

Urothelial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡